High cholesterol secondary prevention: Difference between revisions
Kashish Goel (talk | contribs) No edit summary |
Kashish Goel (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
{{Hypercholesterolemia}} | {{Hypercholesterolemia}} | ||
'''Editor-In-Chief:''' [[C. Michael Gibson, M.S., M.D.]] [mailto:mgibson@perfuse.org] Phone:617-632-7753; '''Associate Editor(s)-In-Chief:''' [[Kashish Goel|Kashish Goel, M.D.]] | '''Editor-In-Chief:''' [[C. Michael Gibson, M.S., M.D.]] [mailto:mgibson@perfuse.org] Phone:617-632-7753; '''Associate Editor(s)-In-Chief:''' [[Kashish Goel|Kashish Goel, M.D.]] | ||
__NOTOC__ | |||
==Overview== | ==Overview== | ||
Patients with [coronary heart disease] or newly diagnosed [acute coronary syndrome] are at a high risk of recurrent coronary events. In addition to modification of lifestyle factors, LDL lowering has been shown to reduce recurrent events, cardiovascular deaths and all-cause mortality in these patients. According to the [NCEP ATP III guidelines], LDL cholesterol of < 100 mg/dL is the goal in patients with CHD and CHD risk equivalents. The NCEP recommendations are mentioned here, in addition to recent evidence. | Patients with [coronary heart disease] or newly diagnosed [acute coronary syndrome] are at a high risk of recurrent coronary events. In addition to modification of lifestyle factors, LDL lowering has been shown to reduce recurrent events, cardiovascular deaths and all-cause mortality in these patients. According to the [NCEP ATP III guidelines], LDL cholesterol of < 100 mg/dL is the goal in patients with CHD and CHD risk equivalents. The NCEP recommendations are mentioned here, in addition to recent evidence. | ||
Revision as of 15:22, 12 September 2011
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-632-7753; Associate Editor(s)-In-Chief: Kashish Goel, M.D.
Overview
Patients with [coronary heart disease] or newly diagnosed [acute coronary syndrome] are at a high risk of recurrent coronary events. In addition to modification of lifestyle factors, LDL lowering has been shown to reduce recurrent events, cardiovascular deaths and all-cause mortality in these patients. According to the [NCEP ATP III guidelines], LDL cholesterol of < 100 mg/dL is the goal in patients with CHD and CHD risk equivalents. The NCEP recommendations are mentioned here, in addition to recent evidence.
Therapy goals
NCEP ATP III guidelines recommended a LDL goal < 100 mg/dL for CHD or CHD risk equivalents, however drug therapy was considered optional between a LDL of 100 to <130 mg/dL. An update by the NCEP committee in 2004 based on new trial data recommended starting drug therapy simultaneously with therapeutic lifestyle changes in CHD patients with LDL < 100 mg/dL. An optional goal of LDL < 70 mg/dL was recommended in high risk patients.